In a recent study published in JAMA Neurology, the AMYPAD consortium demonstrated how useful PET brain scans could be to diagnose patients at different stages of Alzheimer’s disease. The authors were part of the Innovative Medicines Initiative (IMI) funded AMYPAD project, which finished last year. The AMYPAD Diagnostic and Patient Management Study (DPMS) investigated if amyloid PET imaging could improve Alzheimer’s disease diagnosis. Patients in the study had either subjective cognitive decline, mild cognitive impairment or where Alzheimer’s disease was considered in the differential diagnosis. It was led out of the Geneva Memory Centre by Professor Giovanni Frisoni, who worked across eight memory clinics in Europe, and was assisted by Daniele Altomare, the first author on the paper.
We are pleased that the Innovative Health Initiative (IHI, previously known as IMI) featured this recent article on their website and newsletter.
You can read the article here: https://www.ihi.europa.eu/news-events/newsroom/revealing-earlier-and-more-effective-way-diagnose-alzheimers-disease
“The results show the clinical impact of having aetiological information in increasing the diagnostic confidence of the physician.This information could be particularly important in the future as being able to confirm the presence of amyloid is required prior to the initiation of amyloid targeted therapies.”, said Medical Leader Dr Gill Farrar of GE Healthcare.